We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
- Authors
Ayash, L J; Elias, A; Wheeler, C; Reich, E; Schwartz, G; Mazanet, R; Tepler, I; Warren, D; Lynch, C; Gonin, R
- Abstract
Twenty-seven percent of responding metastatic breast cancer patients remain progression-free a median 29 months following one intensification course of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/m2), and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT). European investigators report high complete response (CR) rates with melphalan for breast cancer. This trial studied the feasibility of two tandem high-dose intensification therapies in an attempt to optimize disease response and duration.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Vol 12, Issue 1, p37
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1994.12.1.37